University of Exeter Medical School

Louise Crathorne

Louise Crathorne

Senior Research Fellow in Health Technology Assessment

 L.Crathorne@exeter.ac.uk

 01392 72 7515

 South Cloisters 3.09B

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Louise’s background is in health technology assessment and evidence synthesis. Her interests have spread to health economics, having developed and critique a number of assessments to inform national decision-making for the National Institute for Health and Care Excellence (NICE), and locally for North East and West (NEW) Devon CCG, conducting rapid reviews as well as conducting budget impact analyses. Louise also has experience as a Senior Systematic Reviewer with the National Guidelines Alliance (Royal College of Obstetricians and Gynaecologists), contributing to the development of a number of NICE clinical guidelines.

Louise also has experience as a scientific writer with clinical trials and regulatory writing experience for GSK Vaccines for the meningococcal and chronic obstructive pulmonary disease (COPD) platforms, and has held positions as Head of Medical Writing at leading international medical communications agencies in the UK and Europe. She has also been involved in the production of a wide range of global and regional medical education materials. These have included peer-reviewed publications; meeting, marketing and training materials as well as information for patients. In addition, she has led the preparation of health technology assessment submissions for NICE, Scottish Medicines Consortium (SMC), National Centre for Pharmacoeconomics (NCPE) (Ireland), the National Health Care Institute (Zorginstituut Nederland [ZIN]), and the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]).

Qualifications

  • BA (Hons) English Literature
  • MSc Health Economics and Health Policy (Merit)

Back to top

Research

Research interests

  • Evidence synthesis and systematic review
  • Economic evaluation of health technologies
  • Health technology assessment

Broad research specialisms:

Research interests and activities involve the use of economics and health economics principles to improve decision making in the health setting, and across related areas.

Research projects

  • CEA in dementia and alzheimer’s disease

Grants/Funding:

Co-applicant:

  • Five-year contract from the National Institute for Health Research (NIHR) Health Technology Assessment Programme (NIHR: £3.5 million)
  • MRC Newton Fund grant. Collaboration with the Fundação Oswaldo Cruz Foundation (Fiocruz) in Rio de Janeiro. Evaluation of the clinical and cost-effectiveness of diagnostic and therapeutic interventions for the treatment of hepatitis C: (total awarded not known) (~2014/2015)
  • The best of the UK? A report on the value and future of UK databases in the health and social care fields: (£3,000) (year not known)
  • Pain relief for venous cannulation of adults in routine treatment settings: a systematic review (£15,000) (~2011/2012)

Back to top

Publications

Journal articles

Streeter AJ, Lin NX, Crathorne L, Haasova M, Hyde C, Melzer D, Henley W (In Press). Adjusting for unmeasured confounding in non-randomised longitudinal studies: a methodological review. Journal of Clinical Epidemiology
Wyatt KM, Lloyd JJ, Green C, Hurst A, McHugh C, Logan S, Taylor R, Hillsdon M, Price L, Abraham C, et al (In Press). Cluster randomised controlled trial, economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention (Healthy Lifestyles Programme, HeLP) to prevent obesity in school children. NIHR Public Health Research
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract.
Trigg LA, Barnish MS, Hayward S, Shaw N, Crathorne L, Groves B, Spoors J, Strong T, Melendez-Torres GJ, Farmer C, et al (2024). An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund. Pharmacoecon Open, 8(2), 303-311. Abstract.  Author URL.
Farmer C, Barnish MS, Trigg LA, Hayward S, Shaw N, Crathorne L, Strong T, Groves B, Spoors J, Melendez Torres GJ, et al (2023). An evaluation of managed access agreements in England based on stakeholder experience. International Journal of Technology Assessment in Health Care, 39(1). Abstract.
Farmer C, O’Toole B, Barnish MS, Trigg LA, Hayward S, Crathorne L, Kasten Z, Spoors J, Melendez-Torres GJ (2023). Early access schemes for innovative health technologies: the views of international stakeholders. International Journal of Technology Assessment in Health Care, 39(1). Abstract.
Melendez‐Torres GJ, Crathorne L, Hepworth E, Sloane V, Jackson S, Nicholas R, Cohen CE (2023). Evaluation of an acute trust Domestic Abuse Coordinator role: Impact findings and a budget impact model. The International Journal of Health Planning and Management, 39(2), 563-570. Abstract.
Meisel A, Baggi F, Behin A, Evoli A, Kostera‐Pruszczyk A, Mantegazza R, Juntas Morales R, Punga AR, Sacconi S, Schroeter M, et al (2023). Reply to the Letter to the Editor in response to “Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal”. European Journal of Neurology, 30(4), 1162-1164.
Meisel A, Baggi F, Behin A, Evoli A, Kostera-Pruszczyk A, Mantegazza R, Morales RJ, Punga AR, Sacconi S, Schroeter M, et al (2023). Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal. Eur J Neurol, 30(1), 266-282. Abstract.  Author URL.
Keyzor I, Shohet S, Castelli J, Sitaraman S, Veleva-Rotse B, Weimer JM, Fox B, Willer T, Tuske S, Crathorne L, et al (2023). Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: a Review of the Evidence and Informed Approach to Reclassification. Biomolecules, 13(8), 1227-1227. Abstract.
Jones-Hughes T, Campbell J, Crathorne L (2021). Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review. Orphanet Journal of Rare Diseases, 16(1). Abstract.
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Hatswell AJ, Melendez-Torres GJ, Crathorne L (2020). Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: an Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal. Pharmacoeconomics, 38(12), 1309-1318. Abstract.  Author URL.
Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, Marinho DS, Haasova M, Veloso VG, Anderson R, et al (2018). Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol, 18(1). Abstract.  Author URL.
Tikhonova I, Huxley N, Snowsill T, Crathorne L, Varley-Campbell J, Napier M, Hoyle M (2018). Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Pharmacoeconomics
Snowsill TM, Moore J, Mujica Mota R, Peters JL, Jones-Hughes T, Huxley NJ, Coelho H, Haasova M, Cooper C, Lowe JA, et al (2017). Immunosuppressive agents in adult kidney transplantation in the NHS: a model-based economic evaluation. Nephrology Dialysis Transplantation
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle M, et al (2017). The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technol Assess, 21(38), 1-294. Abstract.  Author URL.
Bond M, Crathorne L, Peters J, Coelho H, Haasova M, Cooper C, Milner Q, Shawyer V, Hyde C, Powell R, et al (2016). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review and network meta-analysis. BMC Anesthesiol, 16(1). Abstract.  Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2016). Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 20(62), 1-594. Abstract.  Author URL.
Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, et al (2016). Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation. Health Technol Assess, 20(61), 1-324. Abstract.  Author URL.
Linton M-J, Dieppe P, Medina-Lara A (2016). Review of 99 self-report measures for assessing well-being in adults: exploring dimensions of well-being and developments over time. BMJ Open, 6(7). Abstract.  Author URL.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2016). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment  Author URL.
Long L, Briscoe S, Cooper C, Hyde C, Crathorne L (2015). What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations. Health Technology Assessment, 19(8), 5-73. Abstract.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). 1498PWHAT IS THE CLINICAL EFFECTIVENESS OF ERYTHROPOIESIS STIMULATING AGENTS FOR THE TREATMENT OF CANCER TREATMENT-INDUCED ANAEMIA?. Ann Oncol, 25(suppl_4), iv523-iv524.  Author URL.
Haasova M, Crathorne L, Huxley N, Hyde C (2014). 1502PWHAT IS THE CLINICAL AND COST EFFECTIVENESS OF ERYTHROPOIETIN-STIMULATING AGENTS FOR THE TREATMENT OF PATIENTS WITH CANCER-TREATMENT INDUCED ANAEMIA? INSIGHTS FROM CUMULATIVE META-ANALYSES (CMA) AND LESSONS FOR COST-EFFECTIVENESS ANALYSES. Ann Oncol, 25(suppl_4).  Author URL.
Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract.  Author URL.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract.  Author URL.
Long HL, Briscoe S, Cooper C, Hyde C, Crathrone L (2013). What is the effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations.
Crathorne L, Bond M, Cooper C, Elston J, Weiner G, Taylor R, Stein K (2012). A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. Clin Otolaryngol, 37(5), 342-354. Abstract.  Author URL.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract.  Author URL.
Cooper C, O'Mara-Eves A, Rogers M, Bethel A, Lowe J, Crathorne L, Gomersall A (2012). The best of the UK? a report on the value and future of UK databases in the health and social care fields: a systematic map protocol. BMJ Open, 2(3). Abstract.  Author URL.
Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2010). Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health Technol Assess, 14(Suppl. 2), 41-46. Abstract.  Author URL.

Conferences

Crathorne L, Reimer E, Harris S, Cohen A (2018). THE COST OF MAJOR BLEEDING EVENTS ASSOCIATED WITH ANTICOAGULATION TREATMENT - AN ESTIMATION OF THE CONTRIBUTION OF THE REVERSAL AGENTS TO THE OVERALL COST OF MAJOR BLEEDING IN a UK SETTING.  Author URL.
Sadler S, Watson L, Crathorne L, Green C (2017). APPROACHES TO MODELLING THE COST-EFFECTIVENESS OF INTERVENTIONS FOR HEART FAILURE: a SYSTEMATIC REVIEW.  Author URL.
Tikhonova IA, Hoyle M, Snowsill T, Crathorne L, Varley-Campbell J, Peters J, Briscoe S, Bond M, Huxley N (2016). Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorecal Cancer. ISPOR.
Haasova M, Jones-Hughes T, Peters J, Snowsill T, Coelho H, Crathorne L, Mujica Mota R, Varley-Campbell J, Huxley N, Moore J, et al (2016). Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses. Health Technology
Assessment international (HTAi). 10th - 14th May 2016. Abstract.
Huxley N, Snowsill T, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mujica-Mota R, Napier M, et al (2014). A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA.  Author URL.
Bond M, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Powell R, Crathorne L (2014). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review. WHO 22nd International HPH Conference.
Snowsill T, Huxley N, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mota MR, Napier M, et al (2014). MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS.  Author URL.
Huxley N, Haasova M, Crathorne L, Hyde C (2014). WHAT IS THE CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ERYTHROPOIETIN-STIMULATING AGENTS FOR THE TREATMENT OF PATIENTS WITH CANCER-TREATMENT INDUCED ANAEMIA? INSIGHTS FROM CUMULATIVE META-ANALYSES (CMA) AND LESSONS FOR COST-EFFECTIVENESS ANALYSES.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST-LINE CHRONIC MYELOID LEUKAEMIA.  Author URL.

Reports

Haasova M, snowsill T, jones-hughes T, crathorne L, cooper C, varley-campbell J, mujica mota R, coelho H, huxley N, lowe J, et al (In Press). Immunosuppressive therapy for kidney transplantation in children and adolescents (review of technology appraisal 99); a systematic review and economic evaluation. , NIHR Health Technology Assessment Programme. Abstract.
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle MW, et al (2015). Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. MTA for NICE.  Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2015). Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85). MTA for NICE.  Author URL.
Crathorne L, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Bond M (2013). Pain relief for peripheral venous cannulation of adults in routine treatment settings: a systematic review. Royal Devon and Exeter Foundation Trust Hospital,  Exeter, University of Exeter.
Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C (2010). Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Submitted to NICE as STA report.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2009). Everolimus for the second-line treatment of advanced and/or metastatic renal cell carcinoma. NIHR HTA, NICE.

Back to top

External Engagement and Impact

Committee/panel activities

  • National Institute for Health and Care Excellence Early Scientific Advice
  • National Institute for Health and Care Excellence Clinical Guidelines ad hoc committee member

Back to top

Teaching

Teaching responsibilities: (Undergraduate, Postgraduate)

  • External:
    • British Association of Pharmaceutical Physicians (BrAPP) PostGraduate Course in Pharmaceutical Medicine Module (The Economics of Healthcare): Introduction to Health Economics and Health Technology Assessment (2017, 2018, and May 2019).

Modules

2024/25

Information not currently available


Back to top

Edit Profile